- New Antibodies
- Crown Antibodies
- Secondary Antibodies
- Stem Cells
- Neurodegeneration >
- Cancer Antibodies
- GPCR Antibodies
- Loading Control Antibodies
- Gene Ontology >
Biological Process > Cellular Compartment > Molecular Function >
- Pathways >
Biocarta > KEGG > Panther >
- Disease >
- Tissue >
- Tag Antibody
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Biological Process >
- FL cDNA Clones
HLA-DRA Antibody (ascites)
Mouse Monoclonal Antibody (Mab)
United StatesOrdering Information
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanKoreaLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamOthers
|AM1941a||0.1 ml||In Stock||
$ 265.00email & fax$ 251.75online
|DISCONTINUED INQUIRE CLICK INQUIRE Add to cart|
- Citations : 0
HLA-DRA Antibody (ascites) - Product info
|Calculated MW||28607 Da|
HLA-DRA Antibody (ascites) - Additional info
|Gene ID 3122|
HLA-DRA; HLA-DRA1; HLA class II histocompatibility antigen, DR alpha chain; MHC class II antigen DRA
This HLA-DRA antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 48-75 amino acids from human HLA-DRA.
Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
HLA-DRA Antibody (ascites) is for research use only and not for use in diagnostic or therapeutic procedures.
HLA-DRA Antibody (ascites) - Protein Information
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single- pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
HLA-DRA Antibody (ascites) - Related products
HLA-DRA Antibody (ascites) - Research Areas
HLA-DRA Antibody (Cat. #AM1941a) western blot analysis in ZR-75-1 cell line lysates (35ug/lane).This demonstrates the HLA-DRA antibody detected the HLA-DRA protein (arrow).
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5.
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Ucisik-Akkaya, E., et al. Mol. Hum. Reprod. 16(10):770-777(2010)
Hamza, T.H., et al. Nat. Genet. 42(9):781-785(2010)
Iwasa, K., et al. J. Neuroimmunol. 225 (1-2), 171-174 (2010) :
Jin, Y., et al. N. Engl. J. Med. 362(18):1686-1697(2010)